[1] Han HS , Ahn GR , Kim H, et al. Diffuse systemic sclerosis in a patient with primary biliary cirrhosis and autoimmune hepatitis overlap syndrome: a case report. Ann Dermatol, 2020, 32(1):69. [2] Giuseppe M, Nastasio S, Sciveres M. Steroid free treatment in autoimmune hepatitis: is azathioprine monotherapy truly a viable option to obtain remission. J Pediatr, 2019, 210(8):56-58. [3] Chen RL, Wang QX, Ma X. Precision medicine for autoimmune hepatitis. J Dig Dis, 2019, 20(7):331-337. [4] Vespasiani-Gentilucci U, Rosina F, Pace-Palitti V, et al. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients inItaly. Scand J Gastroenterol, 2019, 54(10):1274-1282. [5] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015). 中华肝脏病杂志, 2016, 24(1):23-35. [6] 邱德凯, 马雄. 自身免疫性肝病的诊断和治疗. 中华肝脏病杂志, 2005, 13(1):50-51. [7] Sucher E, Sucher R, Gradistanac T, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res , 2019, 2019:107-113. [8] Adiga A, Nugent K. Lupus hepatitis and autoimmune hepatitis (lupoid hepatitis). Am J Med Sci, 2017. 353(4):329-335. [9] Persaud A, Ahmed A, Kakked G, et al. Association of autoimmune hepatitis and cardiovascular disease. Dig Liver Dis, 2019, 51(11):1604-1609. [10] Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: current and future therapeutic options.Liver Int, 2019, 39(6):1002-1013. [11] Sebode M, Hartl J, Vergani D, et al. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int, 2018. 38(1):15-22. [12] Chang C, Tanaka A, Bowlus C,et al. The use of biologics in the treatment of autoimmune liver disease. Expert Opin Inv Drug, 2020, 29(10): 385-398. [13] Li WY, Yang XS, Wang YC. Glucocorticoids in combination with ursodesoxycholic acid in the treatment of autoimmune hepatitis. J Biol Regul Homeost Agents, 2018, 32(2):307-311. [14] Pape SC, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J, 2019, 7(9): 1156-1163. [15] Minaga K, Watanabe T, Chung H, et al. Autoimmune hepatitis andIgG4-related disease. World J Gastroenterol, 2019, 25(19): 2308-2314. [16] Wijaya I. Therole of ursodeoxycholic acid in acute viral hepatitis: an evidence-based case report. Acta Med Indones, 2015, 47(4):352-357. [17] Trauner M, Nevens F, Shiffman ML, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol, 2019, 4(6): 445-453. [18] Montano-Loza AJ, Bhanji RA, Wasilenko S, et al. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther, 2017, 45(4):485-500. [19] Lammert C. Genetic and environmental risk factors for autoimmune hepatitis. Clin Liver Dis (Hoboken), 2019, 14(1):29-32. [20] Kerkar N, Chan A. Autoimmune hepatitis, sclerosing cholangitis, and autoimmune sclerosing cholangitis or overlap syndrome. Clin Liver Dis, 2018, 22(4):689-702. [21] Fan X, Zhu YJ, Men R, et al. Efficacy and safety of immunosuppressive therapy for PBC-AIH overlap syndrome accompanied by decompensated cirrhosis: a real-world study. Can J Gastroenterol Hepatol, 2018, 2018: 1965492. |